You searched for "cardiovascular"

294 results found

The approach to angle-closure glaucoma

Further to my last article in Eye News (print issue) describing the diagnostic approaches to various clinical scenarios in glaucoma, the approach to angle-closure glaucoma (ACG), a situation terrifying for patient and registrar alike, will be discussed. Please refer to...

25 years of OCT

David Huang first described optical coherence tomography (OCT) in 1991, in his seminal paper on the subject in Science. This method developed the work of others on ophthalmic interferometry, which essentially showed that measuring reflected light could be used to...

Eye Capacity: clinical need should drive ophthalmic service provision

Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...

More sensitive visual acuity test for age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...

The role of injection assistant devices in establishing a nurse-led AMD service

The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

A near miss

A 55-year-old gentleman presented with a ‘blurry patch’ to his left eye which he had noticed for the past two months. The visual acuity with correction was 6/5 in the right eye and 6/6 in the left eye on the...

How to survive the fluorescein round

One of the highlights of the medical retina fellowship programme at Moorfields is the Tuesday morning 8am fluorescein round. It is both exhilarating and terrifying. Exhilarating because they are slick presentations of the most interesting cases that each of the...

Turn up anytime

When I was starting off in ophthalmology my then boss had a standard spiel after completing a cataract case. It did not vary and I do not recall an instance of it not taking place. “The operation went well and...

Articles you will never read

I am sad as this is my last article. The last Learning Curve written by me. I have been writing this column for more than 10 years and have enjoyed every moment. I will be eternally grateful to Eye News...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...